M. A. Abdel HAMİD, T. EL-SERGANİ, A. T. SHOHEİR, A. A. SHOUMEN

Pro-inflammatory and Anti-inflammatory Cytokines in Vitreous Fluid of Patients with Proliferative Diabetic Retinopathy

To determine the intra-vitreous levels of two pro-inflammatory cytokines [interleukin-8 (IL-8), monocyte chemoattractant protein-1 (MCP-1)] and the anti-inflammatory cytokine interleukin-10 (IL-10) in patients with proliferative diabetic retinopathy (PDR). In addition, the relationship between the level of cytokines and PDR activity had also been evaluated. The study included 23 diabetic patients with PDR (13 diabetic patients with inactive PDR and 10 diabetic patients with active PDR). Sixteen age-matched non-diabetic patients with macular hole served as a control group. IL-8, MCP-1 and IL-10 were measured by enzyme-linked immunosorbent assay (ELISA). The vitreal levels of both IL-8 and MCP-1 were significantly higher in diabetic patients with PDR in comparison with the control group. In addition, the vitreous concentrations of IL-8 and MCP-1 were higher in patients with active PDR than in those patients with inactive PDR However, no significant difference was detected in the vitreal levels of IL-10 between diabetic patients and the control group. The pro-inflammatory cytokines IL-8 and MCP-1 are increased in the vitreous fluid of PDR patients without an increase in the anti-inflammatory cytokine IL-10. In addition, both intra-vitreous IL-8 and MCP-1 levels are asssociated with PDR activity, thus suggesting that these cytokines may be pathogenically related to PDR

PDF

___

[1] BenEzar D, Maftzir G. 1996: Antibodies to IL-1 and TNF- α but not to bFGF or VEGF inhibit angiogenesis. Invest Ophtha lmol Vis Sci ; 37:4664– 4670.
[2] Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell SE, Adamis AP. 2001: Leukocyte-mediated endothelial cell injury and death in the diabetic Retina Am J Pathol.; 158: 147–152.
[3] Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW. 2002:Diabetic retinopathy: more than meets the eye.Surv Ophthalmol; 47(Suppl. 2): S253– 262.
[4] Mohr. Potential new strategies to prevent the development of diabetic retinopathy. Expert. Opin. Investig. Drugs 2004;13: 189–198.
[5] Taub DD, Anver M, Oppenheim JJ, Longo DL, Murphy WJ. 1996:T-lymphocyte recruitment by interleukin-8 (IL-8): Il−8 induced degranulation of neutrophils releases potent chemoatractants for human T lymphocytes both in vivo and in vitro. J Clin. Invest; 97: 1931–1941.
[6] Huang S, Ullrich SE, Bar-Eli M. 1999: Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. J Interferon Cytokine Res.; 19: 697–703.
[7] Stearns Garcia FU, Fudge K, Rhim J, Wang M. 1999: Role of interleukin 10 and transforming growth factor β1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice. Clin Cancer Res 5: 711–720.
[8] Silvestre JS, Mallat Z, Duriez M, Tamarat R, Bureau MF, Scherman D et al. 2000: Antiangiogenic effect of interleukin-10 in ischemia-induced angiogenesis in mice hind limb. Circ Res; 87: 448–452.
[9] Heinemann, A. et al. (2000) J. Immunol. 165:7224 [10] Maquart FX, Gillery P, Bernar JF, Mante TP, and Borel JP. 1980: A method specifically measuring hemoglobin A1c with disposable commercial ion exchange column. Clin. Chem. Acta,; 108: 329-332.
[11] Yuuki T, Kanda T, Kimura Y, Kotajima N, Tamura J, Kobayashi Iet al. 2001 Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J Diabetes Complications ; 15: 257–259.
[12] Cicik E, Tekin H, Akar S, Ekmekci OB, Donma O, Koldas L et al. 2003: Interleukin-8, nitric oxide and glutathione status in proliferative vitreo-retinopathy and proliferative diabetic retinopathy. Ophthalmic Res; 35:251–255.
[13] Petrovic MG, Korosec P, Kosnik M and Hawlina M. 2007 : Vitreous levels of interleukin-8 in patients with proliferative diabetic retinopathy. Am J Ophthalmol , 143:175-176
[14] Murugeswari P, Shuklia D, Rajendran A, et al. 2008: Proinflammatory cytokines and angiogenic and antiangiogenic factrs in vitreous of patients with proliferative diabetic retinopathy and Eales disease. Retina 28:817-824,
[15] Capeans C, De Rojas MV, Lojo S, Salorio. 1998: CC chemokines in the vitreous of patients with proliferative vitreo-retinopathy and proliferative diabetic retinopathy. Retina; 18: 546–550.
[16] El-Ghrably IA, Dua HS, Orr GM, Fisher D, Tighe PJ. Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy. Br J Ophthalmol 2002; 85: 461–470.
[17] Yoshida A, Yoshida S, Khalil AK, Ishibashi T, Inomata H. 1998: Role of NF-kappaB-mediated interleukin-8 expression in intraocular neovascularization. Invest Oph thalmol Vis Sci ;39: 1097–1106.
[18] Chan CC, Buggage RR, Nussenblat RB. 2002: Intraocular lymphoma. Curr Opin Ophthalmol;13: 411–418.
[19] van Exel E, Gussekloo J, de Craen AJ, Frölich M, Bootsma-Van Der Wiel A, Westendorp RGJ. 2002: Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes. The Leiden85-Plus Study.Diabetes; 51: 1088–1092.